Hair Loss in Trans Men on Testosterone: Pattern and Timing

Testosterone therapy for transmasculine patients produces the androgen exposure that drives male pattern hair loss in genetically susceptible individuals. Hair changes are among the most discussed effects of testosterone therapy, with both intended (body and facial hair growth) and unintended (scalp hair loss in pattern distribution) consequences. The timing and pattern of scalp hair loss in this population provides useful information about androgen response dynamics.

Scalp hair loss in trans men on testosterone typically begins 2 to 5 years after testosterone initiation, with strong dependence on genetic susceptibility, family history of male pattern hair loss strongly predicts which individuals will experience clinically significant loss. Pattern distribution follows the standard Norwood pattern (frontal recession and vertex thinning), and progression rates are similar to cisgender men with equivalent androgen exposure and genetic background.

Treatment considerations include the standard finasteride and minoxidil options, with some additional considerations. Finasteride blocks DHT but doesn't affect testosterone levels, important reassurance for patients prioritising masculinising effects, since beard growth, voice deepening, and body fat distribution depend on testosterone rather than DHT. Patients with strong family history of pattern hair loss who are starting testosterone may consider prophylactic finasteride if hair preservation is a priority. The conversation about hair changes during informed consent for testosterone therapy should include both the likely beard/body hair changes and the possible scalp hair implications.